Markets:

Overview

News

Currencies

International

Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.510 -0.090 (-5.63%)

Official Closing Price Updated: 8:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 12, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 12, 2024

Via Benzinga

Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket ↗

January 12, 2024

Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 12, 2024

We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

October 31, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 09, 2024

Via Benzinga

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

January 05, 2024

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

December 19, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

November 17, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

November 17, 2023

Via ACCESSWIRE

What's Going On With Crispr Therapeutics Stock Thursday? ↗

November 16, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene-

Via Benzinga

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer ↗

November 16, 2023

More than 300,000 people are diagnosed with brain cancer across the globe each year.

Via Benzinga

Why MAIA Biotechnology Stock Is Nosediving During Wednesday's Session ↗

November 15, 2023

MAIA Biotechnology Inc (NASDAQ: MAIA) shares are trading lower by 20.97% to $1.47 Wednesday morning after the company announced it's finalizing a deal to sell about 2.4 million shares of its common...

Via Benzinga

MAIA Biotechnology Announces $4 Million Registered Direct Offering

November 15, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

November 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

November 07, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

October 30, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer ↗

October 30, 2023

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.

Via Benzinga

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

October 24, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

October 19, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy

October 17, 2023

Via ACCESSWIRE

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023

October 17, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy ↗

October 16, 2023

Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children.

Via Benzinga

MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

October 12, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

October 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

October 10, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 05, 2023

Via Benzinga

MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer ↗

October 03, 2023

MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 03, 2023

Via Benzinga

MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

October 03, 2023

From MAIA Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.